Oxford BioDynamics reports interim results with rising PSE sales and new CEO, but faces near-term funding need

Oxford BioDynamics interim results 2026: stronger PSE sales are real progress

Oxford BioDynamics has delivered a mixed set of interim results for the six months to 31 March 2026. The encouraging bit is clear enough – sales of its EpiSwitch PSE prostate screening blood test kept climbing, revenue moved up, and the operating loss narrowed. The awkward bit is just as clear – the business still needs more cash, and it needs it soon.

That combination matters. For retail investors, this is one of those updates where the commercial story is getting more believable, but the balance sheet is still calling the tune.

Key Oxford BioDynamics H1 2026 numbers at a glance

Metric	H1 2026	H1 2025
Revenue	£0.69 million	£0.59 million
Operating loss	£4.68 million	£5.88 million
Cash and cash equivalents	£2.51 million	Not disclosed for H1 2025 in highlights
Cash at 31 May 2026	£1.38 million	Not disclosed
PSE test orders	1,788	791
Increase in PSE orders vs H1 2025	126%	–
Average staff numbers	37	44

On the face of it, those numbers show improvement. Revenue rose by roughly £0.10 million year-on-year, while the operating loss came down by £1.20 million. That is not enough to make the business self-funding, but it does show management is at least moving in the right direction operationally.

Oxford BioDynamics PSE sales growth: the biggest positive in the results

The standout line in this RNS is PSE. Oxford BioDynamics sold 1,788 tests in the period, up 66% on H2 2025 and up 126% on H1 2025. More than 5,000 PSE tests have now been sold since launch in September 2023, with over half of those sales coming in the current financial year.

That is important because PSE is doing the heavy lifting commercially. The company said almost all revenue in the period came from clinical test sales, and almost all of that was PSE. Total revenue was £687k, with £587k from the USA and £100k from the rest of the world.

My read is simple: investors wanted proof that demand for PSE was not just theoretical. They have now got a better answer. It is still early-stage, but the growth rate is strong enough to suggest the product is finding genuine traction in the US market.

Why the US commercial setup matters for PSE growth

Management says it has tripled the number of active high-ordering anchor clinics since 30 September 2025 and switched to independent contractors for US sales. Post period-end, it also appointed MK Commercial Group, which immediately increases field presence by around 60%.

That is a smart move if it works. A larger sales footprint with lower fixed costs is exactly what a cash-constrained diagnostics business should be aiming for. It gives OBD a better shot at accelerating orders without stuffing the cost base full of new full-time hires.

One more useful detail: approximately 20% of global PSE test sales were cash-pay, with the rest reimbursed through US insurance. Reimbursement matters because it often decides whether a test scales properly or stays niche. OBD says reimbursement remains strong and it is working on claims processing and more real-world evidence to support wider adoption.

Richard Compton as new CEO could sharpen the commercial focus

The appointment of Richard Compton as Chief Executive Officer looks sensible. Chairman Iain Ross is basically admitting that strong science has not yet been matched by strong enough commercial execution, and Compton has the diagnostics background the board thinks it needs.

He has held senior commercial roles at Oxford Nanopore and Illumina, and has more recently advised OBD. That does not guarantee success, of course, but it does suggest the company is serious about shifting from scientific promise to commercial delivery.

For me, this matters more than the usual boardroom shuffle. When a small biotech or diagnostics firm is running short on cash, the market wants someone who can sell products, sign deals and talk credibly to investors. That is the job description here.

EpiSwitch Orion and ME/CFS test add upside, but revenue is not here yet

There are two interesting growth stories beyond PSE. First is EpiSwitch Orion, the new cloud-based 3D genomics platform launched in March 2026. In plain English, OBD says Orion can extract fresh insight from existing DNA sequencing datasets, potentially saving pharma companies time and money.

The company says Orion has been introduced into several research centres and is now in commercial discussions with three large pharma companies. That is promising, but this is still pre-revenue in practical terms. The first commercial usage agreements are in negotiation, not signed.

Second is the ME/CFS blood test. OBD announced this in October 2025 and says it is aiming to make the test commercially available before the end of the current calendar year. Interest appears strong from academia and industry, but the company is seeking non-dilutive or grant funding for the programme, which tells you it does not want to fund the rollout entirely from its own thin cash resources.

These projects absolutely matter for valuation because they broaden the story beyond prostate screening. But retail investors should be careful not to count hoped-for revenues before they arrive. Right now, PSE is the product paying the bills, and even that is not yet paying enough of them.

Oxford BioDynamics cash runway and going concern warning: this is the big risk

Here is the part that cannot be dressed up. Cash and cash equivalents were £2.51 million at 31 March 2026, but had dropped to £1.38 million by 31 May 2026. The company says it requires additional funds by late August 2026.

That is why the going concern wording matters. A going concern statement means the directors believe the business can keep operating, but OBD also says there is a material uncertainty which may cast significant doubt on that ability. In retail investor language: they think they can raise the money, but they cannot promise it.

The company’s internal forecast assumes at least £3 million in equity funding during calendar Q3 2026. It also assumes revenue growth from PSE, pharma work including Orion, and potential outlicensing deals. If those do not land, the downside scenario suggests more funding would be needed during Q1 2027.

Why dilution remains a live issue for shareholders

OBD raised £7 million gross in November 2025 by issuing 2,333,333,326 new ordinary shares at £0.003 each, with £0.68 million of transaction costs. That was a necessary lifeline, but it came at a historically low issue price and involved significant dilution for investors who did not participate.

This is the uncomfortable trade-off. The company is buying time to grow PSE and secure commercial deals, but that time has been purchased partly by issuing a huge number of new shares. If more equity funding is needed in the near term, dilution risk remains very real.

Cost cutting is helping, but Oxford BioDynamics is still burning cash

To give management credit, costs are moving the right way. Staff costs fell to £2.07 million from £2.59 million, average headcount dropped from 44 to 37, and general and administrative costs came down to £1.77 million from £2.42 million.

That discipline helped narrow the operating loss, and net cash used in operating activities improved to £4.47 million from £4.87 million. Even so, this is still a business with a meaningful cash burn and no margin for delay if sales or deals disappoint.

What Oxford BioDynamics interim results mean for retail investors

My view is that this was operationally better than it was financially comfortable. PSE sales growth is strong, the new CEO appointment looks logical, and there are credible medium-term opportunities in Orion and ME/CFS. Those are the reasons the story is still alive.

But the immediate investment case is dominated by funding risk. Until OBD secures fresh cash and proves it can turn product momentum into much larger revenue, the shares are likely to trade more on financing news than on scientific potential.

So the verdict is mixed. The business is showing signs of commercial life, which is positive. The balance sheet is still tight enough to keep investors on edge, which is the bit that really matters over the next few months.